Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Systems Biology Phase 1 Evaluation of the Safety, Reactogenicity, and Immunogenicity of Chimpanzee Adenovirus Type 3- Vectored Zaire Ebolavirus (ChAd3-EBO-Z) and Modified Vaccinia Ankara- Vectored Multivalent Filovirus (MVA-BN(R)-Filo) Vaccine Candidates

Trial Profile

A Systems Biology Phase 1 Evaluation of the Safety, Reactogenicity, and Immunogenicity of Chimpanzee Adenovirus Type 3- Vectored Zaire Ebolavirus (ChAd3-EBO-Z) and Modified Vaccinia Ankara- Vectored Multivalent Filovirus (MVA-BN(R)-Filo) Vaccine Candidates

Recruiting
Phase of Trial: Phase I

Latest Information Update: 04 Jan 2019

At a glance

  • Drugs GSK 3390107A (Primary) ; Modified Vaccinia Ankara Bavarian Nordic Ebola Marburg vaccine
  • Indications Ebola virus infections
  • Focus Adverse reactions; Proof of concept
  • Most Recent Events

    • 25 Oct 2018 Status changed from not yet recruiting to recruiting.
    • 11 Oct 2018 Planned initiation date changed from 11 Oct 2018 to 1 Nov 2018.
    • 20 Sep 2018 Planned initiation date changed from 20 Sep 2018 to 11 Oct 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top